In our results, however, IL-17 did not seem to have an adverse impact on prognosis of AML, because IL-17 was inversely correlated with the percentage of CD45dimCD34+CD38−CD133+ LSCs which was shown to be a significant negative prognostic marker, considering together clinical factors. This evidence concerns the gene IL17A and acute myeloid leukemia.